The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ALS in the EU.

CHMP upheld earlier opinions that Translarna is not of significant benefit to DMD due to nonsense mutations; European ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company’s President ...

First major treatment advance in nearly 25 years; Gliomas target individuals in the prime of life, often in their 30s and 40s ...

Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, ...

Samsung Biologics landed a $1.24 billion contract manufacturing deal with an Asian pharmaceutical giant, shattering its ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

BeiGene (BGNE) announced that the Committee for Medicinal Products for Human Use – CHMP – of the European Medicines Agency issued ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The fully-owned Intas Pharmaceuticals subsidiary Accord Healthcare has announced that the Committee for Medicinal Products ...

The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for ...